Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec;38(12):2709-2711.
doi: 10.1038/s41375-024-02420-6. Epub 2024 Sep 25.

Pola-R-CHP or R-CHOEP for first-line therapy of younger patients with high-risk diffuse large B-cell lymphoma: a retrospective comparison of two randomized phase 3 trials

Georg Lenz  1 , Hervé Tilly  2 , Marita Ziepert  3 , Bettina Altmann  3 , Charles Herbaux  4 , Fabian Frontzek  5 , Maike Nickelsen  6 , Calvin Lee  7 , Jamie Hirata  7 , Deniz Sahin  8 , Saibah Chohan  9 , Connie Lee Batlevi  7 , Mark Yan  9 , Franck Morschhauser  10 , Norbert Schmitz  5
Affiliations

Pola-R-CHP or R-CHOEP for first-line therapy of younger patients with high-risk diffuse large B-cell lymphoma: a retrospective comparison of two randomized phase 3 trials

Georg Lenz et al. Leukemia. 2024 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests: GL received research grants not related to this manuscript from AGIOS, AQUINOX, AstraZeneca, Bayer, Celgene, Gilead, Janssen, MorphoSys, Novartis, F. Hoffmann-La Roche Ltd, and Verastem. GL received honoraria from ADC Therapeutics, AbbVie, Amgen, AstraZeneca, Bayer, BeiGene, BMS, Celgene, Constellation, Genase, Genmab, Gilead, Hexal/Sandoz, Immagene, Incyte, Janssen, Karyopharm, Lilly, Miltenyi, MorphoSys, MSD, NanoString, Novartis, PentixaPharm, Pierre Fabre, F. Hoffmann-La Roche Ltd, and Sobi.

Figures

Fig. 1
Fig. 1. Survival of DLBCL patients treated with R-CHOEP or Pola-R-CHP respectively.
Kaplan–Meier estimates of PFS (A) and OS (B). PFS at 2 years was 72.4% (95.0% CI 62.9%–81.8%) after R-CHOEP and 74.8% (95.0% CI 66.5%–83.0%) after Pola-R-CHP, respectively. The OS at 2 years was 81.7% (95.0% CI 73.6%–89.8%) after R-CHOEP and 88.3% (95.0% CI 82.3%–94.3%) after Pola-R-CHP. CI confidence interval, OS overall survival, PFS progression-free survival.
See this image and copyright information in PMC

References

    1. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–42. - PubMed
    1. Cunningham D, Hawkes EA, Jack A, Qian W, Smith P, Mouncey P, et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet. 2013;381:1817–26. - PubMed
    1. Pfreundschuh M, Poeschel V, Zeynalova S, Hanel M, Held G, Schmitz N, et al. Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the German high-grade non-Hodgkin lymphoma study group. J Clin Oncol. 2014;32:4127–33. - PubMed
    1. Friedrichs B, Nickelsen M, Ziepert M, Altmann B, Haenel M, Viardot A, et al. Doubling rituximab in high-risk patients with aggressive B-cell lymphoma -results of the DENSE-R-MegaCHOEP trial. Brit J Haematol. 2019;184:760–68. - PubMed
    1. Lugtenburg PJ, de Nully Brown P, van der Holt B, D’Amore FA, Koene HR, de Jongh E, et al. Rituximab-CHOP with early rituximab intensification for diffuse large B-cell lymphoma: a randomized phase III trial of the HOVON and the nordic lymphoma group (HOVON-84). J Clin Oncol. 2020;38:3377–87. - PubMed

LinkOut - more resources